The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in Chinese patients with unresectable or metastatic melanoma: Results from LEAP-003.
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Xiaoshi Zhang
No Relationships to Disclose
 
Di Wu
No Relationships to Disclose
 
Lu Si
Honoraria - MSD; Novartis; Shanghai Junshi Biosciences; Shanghai Kezhou Pharmaceutical
 
Ya Ding
No Relationships to Disclose
 
Zhiguo Luo
Research Funding - China Postdoctoral Science Foundation (I); Shanghai Anticancer Association Program
 
Xiubao Ren
No Relationships to Disclose
 
Zhengyun Zou
No Relationships to Disclose
 
Yu Chen
No Relationships to Disclose
 
Meiyu Fang
No Relationships to Disclose
 
Ke Li
No Relationships to Disclose
 
Quanli Gao
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Chinyere Okpara
Employment - Eisai
 
Wei Wang
Stock and Other Ownership Interests - MSD
 
Shanshan Chen
Employment - Merck & Sharp Dohme; Roche China
 
Mizuho Fukunaga-Kalabis
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Ana Arance
Consulting or Advisory Role - Almirall; Biontech; BMS GmbH & Co. KG; Genmab; MSD; Pierre Fabre
Speakers' Bureau - BMS; MSD; Pierre Fabre
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - MSD; Pierre Fabre